Hematopoietic Stem Cell Transplantation Activity in China 2020–2021 During the SARS-CoV-2 Pandemic: A Report From the Chinese Blood and Marrow Transplantation Registry Group

[1]  I. Yakoub-Agha,et al.  Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey , 2022, Bone Marrow Transplantation.

[2]  Shunqing Wang,et al.  Long-term follow-up of haploidentical transplantation in relapsed/refractory severe aplastic anemia: a multicenter prospective study. , 2022, Science bulletin.

[3]  M. Krem,et al.  Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia , 2021, Blood advances.

[4]  He Huang,et al.  The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update , 2021, Journal of Hematology & Oncology.

[5]  He Huang,et al.  Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group , 2021, Bone Marrow Transplantation.

[6]  N. Kröger,et al.  Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT , 2021, Journal of Hematology & Oncology.

[7]  M. Aljurf,et al.  Clinical course and outcomes of COVID‐19 in hematopoietic cell transplant patients, a regional report from the Middle East , 2021, Bone Marrow Transplantation.

[8]  Yu Wang,et al.  G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Acute Leukemia Patients in the First Complete Remission: A Registered Study , 2021, Frontiers in Oncology.

[9]  A. Nagler,et al.  How Do We Manage Hematopoietic Cell Transplant during the SARS-CoV-2 Pandemic? , 2021, Acta Haematologica.

[10]  A. Velardi,et al.  Haplo‐identical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: Results from the Severe Aplastic Anemia Working Party of the EBMT , 2021, American journal of hematology.

[11]  S. Seitz,et al.  Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS , 2020, Bone Marrow Transplantation.

[12]  W. Wood,et al.  Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Commi , 2020, Biology of Blood and Marrow Transplantation.

[13]  S. Montoto,et al.  Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy , 2020, Bone Marrow Transplantation.

[14]  S. Montoto,et al.  The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. , 2020, Bone marrow transplantation.

[15]  S. Montoto,et al.  The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy , 2020, Bone Marrow Transplantation.

[16]  M. Labopin,et al.  Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia , 2020, Leukemia.

[17]  M. Labopin,et al.  Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT , 2020, Journal of Hematology & Oncology.

[18]  S. Montoto,et al.  Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019 , 2019, Bone Marrow Transplantation.

[19]  Libo Zhao,et al.  Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis. , 2019, Critical reviews in oncology/hematology.

[20]  He Huang,et al.  The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology , 2018, Journal of Hematology & Oncology.

[21]  L. Xu,et al.  A review of hematopoietic cell transplantation in China: data and trends during 2008–2016 , 2017, Bone Marrow Transplantation.

[22]  Shunqing Wang,et al.  Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant , 2017, Journal of Hematology & Oncology.

[23]  S. Theurich,et al.  Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. , 2014, The Cochrane database of systematic reviews.

[24]  A. Gratwohl,et al.  Hematopoietic stem cell transplantation: a global perspective. , 2010, JAMA.

[25]  Edward A Copelan,et al.  Hematopoietic stem-cell transplantation. , 2006, The New England journal of medicine.